| Joyce Lynn Goglin, CNM | |
|
810 Ellis Ave, Ashland, WI 54806-3158 | |
| (563) 556-5301 | |
| Not Available |
| Full Name | Joyce Lynn Goglin |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 810 Ellis Ave, Ashland, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124132477 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | B056654 (Iowa) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Joyce Lynn Goglin, CNM 810 Ellis Ave, Ashland, WI 54806-3158 Ph: () - | Joyce Lynn Goglin, CNM 810 Ellis Ave, Ashland, WI 54806-3158 Ph: (563) 556-5301 |
News Archive
A nearly $2 million grant from the National Institutes of Health will help investigators at Nationwide Children's Hospital search for biomarkers that may be linked to the development and outcome of hemangiomas, the most common soft tissue tumor in children.
The U.S. plans to support efforts to develop a sustainable health system in Zimbabwe and increase its capacity to treat people, Eric Goosby, U.S. global AIDS Coordinator for PEPFAR, said on Wednesday after a visit to the country with USAID and CDC officials, according to a press release from the U.S. Embassy in Harare, Zimbabwe. Goosby said he is "optimistic" that the Zimbabwe PEPFAR team's experience will be used "to develop a response that fits the existing health infrastructure, supports it and reinforces it in a way that creates a durable and lasting response" (9/2).
American Pharmaceutical Partners, Inc. and American Bioscience, Inc. (ABI) announced that the U.S. Food and Drug Administration (FDA) has approved Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in metastatic breast cancer.
A newly accessible vaccine against Japanese encephalitis (JE) is going to make the protection of more children in developing countries easier. The vaccine, manufactured in China, only needs to be given in one dose, it can be used for infants, and it is less expensive than other Japanese encephalitis vaccines.
All of us who have been at this task before understand three important realities: One, no president who has launched such an effort unsuccessfully has ever been able to relaunch; two, the Senate legislation, at least, has been the product of much bipartisan effort over the last several years, even though no Republican senators voted for it, and three, the status quo costs and quality of this country's health care system are totally unacceptable - to the health care industry and to those who depend on it (Dave Durenberger, 2/18).
› Verified 2 days ago